Login / Signup

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.

Sanja StevanovićAnna PasettoSarah R HelmanJared J GartnerTodd D PrickettBryan HowieHarlan S RobinsPaul F RobbinsChristopher A KlebanoffSteven A RosenbergChristian S Hinrichs
Published in: Science (New York, N.Y.) (2017)
Immunotherapy has clinical activity in certain virally associated cancers. However, the tumor antigens targeted in successful treatments remain poorly defined. We used a personalized immunogenomic approach to elucidate the global landscape of antitumor T cell responses in complete regression of human papillomavirus-associated metastatic cervical cancer after tumor-infiltrating adoptive T cell therapy. Remarkably, immunodominant T cell reactivities were directed against mutated neoantigens or a cancer germline antigen, rather than canonical viral antigens. T cells targeting viral tumor antigens did not display preferential in vivo expansion. Both viral and nonviral tumor antigen-specific T cells resided predominantly in the programmed cell death 1 (PD-1)-expressing T cell compartment, which suggests that PD-1 blockade may unleash diverse antitumor T cell reactivities. These findings suggest a new paradigm of targeting nonviral antigens in immunotherapy of virally associated cancers.
Keyphrases
  • cell therapy
  • dendritic cells
  • sars cov
  • squamous cell carcinoma
  • stem cells
  • drug delivery
  • diabetic rats
  • childhood cancer
  • squamous cell
  • lymph node metastasis